WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > MPRO
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
biotech | September 26, 2016
Scientists can improve protein-based drugs by reaching into the evolutionary past, a paper published in Nature Biotechnology proposes. As a proof of concept for this approach, the research team from Emory, Children's Healthcare of Atlanta and Georgia Tech showed how "ancestral sequence reconstruction" or ASR can guide engineering of the blood clotting protein known as factor VIII, which is deficient in the inherited disorder hemophilia A....
Pall Corporation | October 04, 2016
Pall Corporation, a global leader in filtration, separation and purification, is pleased to announce the launch of breakthrough technologies that for the first time enable integrated, process-scale continuous production of biotherapies in single-use formats. Biopharmaceutical manufacturers are increasingly incorporating continuous technologies to replace traditional batch methods in order to improve consistency, reduce production footprints and shorten lead times. Single-use technologies further...
biotech | March 07, 2017
Despite ominous warnings from the scientific establishment that President Trump is anti-science, there is one area in which he might be more pro-science than President Obama: agriculture. Free from the constraints of hard-line, Obama-era environmentalists who opposed innovations such as genetically engineered crops, the Trump administration can energize the federal government’s sclerotic approach to green-lighting new agricultural biotechnologies. Many groundbreaking products could reduce ...
FierceBiotech | January 17, 2020
China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite. It hit $14 a share, the midpoint in the range, and becomes the first Chinese biotech in more than two years (the last being Zai Lab back in 2017) to gain a U.S. IPO. According to recent reports out of Bloomberg, however, it had been quietly hoping for a $200 million offering. The offering seems relatively tame after the monster raises it has gained over the years, including $22...
Cell and Gene Therapy, Industrial Impact
Video
Whitepaper
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE